Myotonic Dystrophy Type 2
Symptoms, Doctors, Treatments, Advances & More

Myotonic Dystrophy Type 2 Overview

Save information for later
Sign Up

Learn About Myotonic Dystrophy Type 2

What is the definition of Myotonic Dystrophy Type 2?
Myotonic dystrophy type 2, one of the two types of myotonic dystrophy, is an inherited muscular dystrophy that affects the muscles and other body systems (e.g., heart, eyes, and pancreas). It is characterized by prolonged muscle tensing (myotonia) as well as muscle weakness, pain, and stiffness. Signs and symptoms usually develop during a person's twenties or thirties. Muscles in the neck, fingers, elbows, and hips are typically affected; facial and ankle muscles are less commonly involved. The severity of Myotonic dystrophy type 2 varies widely among affected people, even among family members. It is inherited in an autosomal dominant pattern and is caused by genetic changes in the CNBP gene.
What are the alternative names for Myotonic Dystrophy Type 2?
  • Myotonic dystrophy type 2
  • DM2
  • Dystrophia myotonica type 2
  • Myotonic myopathy, proximal
  • PROMM
  • Proximal myotonic myopathy
  • Ricker syndrome
Who are the top Myotonic Dystrophy Type 2 Local Doctors?
Elite in Myotonic Dystrophy Type 2
Elite in Myotonic Dystrophy Type 2
Referral may be required

Clinical Research Center

4350 Shawnee Mission Parkway, 
Fairway, KS 
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Statland is a Neurologist practicing medicine in Fairway, Kansas. Dr. Statland is rated as an Elite provider by MediFind in the treatment of Myotonic Dystrophy Type 2. He is also highly rated in 51 other conditions, according to our data. His clinical expertise encompasses Facioscapulohumeral Muscular Dystrophy (FSHD), Paramyotonia Congenita, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, and Gastrostomy. Dr. Statland is board certified in American Board Of Psychiatry And Neurology, Neurology - 2011. Dr. Statland is currently accepting new patients.

Distinguished in Myotonic Dystrophy Type 2
Distinguished in Myotonic Dystrophy Type 2
Referral may be required

OSF Illinois Neurological Institute - Neurology

200 East Pennsylvania Avenue, 
Peoria, IL 
309-624-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gregory Blume is a Neurologist practicing medicine in Peoria, Illinois. Dr. Blume is rated as a Distinguished provider by MediFind in the treatment of Myotonic Dystrophy Type 2. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Myasthenia Gravis, Paramyotonia Congenita, Myotonic Dystrophy Type 2, and Myotonic Dystrophy. Dr. Blume is board certified in American Board Of Psychiatry And Neurology. Dr. Blume is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Myotonic Dystrophy Type 2
Elite in Myotonic Dystrophy Type 2
Referral may be required
Milan, IT 

Giovanni Meola practices practicing medicine in Milan, Italy. Mr. Meola is rated as an Elite expert by MediFind in the treatment of Myotonic Dystrophy Type 2. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Paramyotonia Congenita, Myotonic Dystrophy, Myotonic Dystrophy Type 2, Myotonia Congenita, and Thymectomy.

View All Doctors
What are the latest Myotonic Dystrophy Type 2 Clinical Trials?
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (Delpacibart Zotadirsen) for the Treatment of DMD With Gene Mutations Amenable to Exon 44 Skipping
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (Delpacibart Zotadirsen) for the Treatment of DMD With Gene Mutations Amenable to Exon 44 Skipping
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Drug
Study Phase: Phase 3

Summary: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping

Match to trials
Find the right clinical trials for you in under a minute
Get started
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
Enrollment Status: Recruiting
Publish Date: September 04, 2026

Summary: Myotonic Dystrophy type 1 (DM1) is an autosomal dominant multisystemic disorder that causes progressive disability and shortened life expectancy. It is characterized by progressive weakness and myotonia, which preferentially affects the craniofacial, hand, and distal leg muscles. Many patients also experience difficulties with cognition, cardiac arrhythmias, respiratory failure, or cataracts. Curr...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center